Company Overview
Clearmind Medicine Inc. operates as a clinical stage pharmaceutical entity dedicated to the development of novel psychedelic medicines aimed at addressing under-served health problems within the healthcare sector. Specifically, the company focuses on the biotechnology industry by creating treatments for conditions including alcohol use disorders, binge drinking, eating disorders, weight loss, obesity, metabolic syndrome, and anxiety. The company's current market capitalization stands at $1.70M, while its annual revenue and employee count are not reported in the available data. This valuation indicates that Clearmind Medicine Inc. is a micro-cap entity with limited historical financial performance data to assess its commercial scale, suggesting it remains in an early-stage development phase where revenue generation has not yet materialized into significant market share.
Financial Health
The company reports a Net Income of $-6,639,945 and an EBITDA of $-7,819,964 for the trailing twelve months, while annual revenue remains unquantified in the provided records. The substantial gap between reported revenue figures and negative net income reveals a cost structure dominated by research and development expenses that far exceed current sales, a typical characteristic of clinical-stage biotechnology firms. Free cash flow is reported at $-5,386,203, indicating that the company is currently consuming cash reserves to fund its operations and development pipeline rather than generating liquidity. Gross margin, operating margin, and profit margin are all recorded at 0.0%, reflecting a business model where revenue does not yet cover the direct costs of production or overhead, resulting in a lack of profitability at the gross, operating, and net levels. The company holds $10.35M in cash against a debt level of only $7,977, creating a highly conservative balance sheet with a debt-to-equity ratio of 0.10. This minimal leverage suggests the firm is not utilizing significant debt financing, relying instead on equity or cash reserves to support its activities. The current ratio stands at 3.79, which indicates a strong ability to meet short-term obligations with its liquid assets, although the utility of this liquidity is primarily for sustaining operations until product commercialization. Return on Equity is -119.7% and Return on Assets is -55.2%, metrics that reveal management is currently generating negative returns on the capital invested in the company. These negative return figures are consistent with the net loss position and indicate that the company is not yet profitable enough to provide a return on the shareholder capital or asset base.
Valuation Assessment
Trailing P/E and forward P/E ratios are both unavailable (N/A) due to the company's lack of positive earnings, meaning the difference between them cannot be analyzed in terms of an expected earnings trajectory at this time. The price-to-book ratio is 0.15, which indicates that the market is valuing the company at a significant discount to its book value, a common valuation characteristic for distressed or pre-profitability biotech firms. Price-to-sales and EV/EBITDA metrics are either unavailable or calculated as 1.10 for EV/EBITDA, suggesting that traditional valuation multiples based on earnings or sales efficiency are not applicable or are extremely high relative to current financial performance. The 52-week high is $52.40 and the 52-week low is $0.59, placing the current trading price in a wide range that reflects high price volatility often seen in speculative micro-cap stocks. The beta value is -1.05, which implies that the stock price moves inversely to the broader market or with a volatility profile that is highly sensitive to market sentiment, deviating significantly from the standard positive correlation seen in most equity instruments.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are not available in the provided data, preventing a direct comparison of whether earnings are growing faster or slower than revenue. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, instead choosing to reinvest its remaining earnings or capital into growth initiatives rather than providing income to shareholders. The overall growth and income profile is characterized by a complete absence of current profitability, with all financial resources directed toward advancing clinical development rather than generating shareholder returns through dividends or earnings expansion.